Boehringer Ingelheim steps up its commitment to sustainable development, building on its historical success in addressing unmet health needs and increasing its ambitions to tackle global health and societal challenges.
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Discover the reality of life with schizophrenia through the stories of people who are breaking down the stigma of living with a serious mental illness.
In this article, we’re taking a look at global developments while highlighting one of the most important meat markets of the future: the Asian continent.
Maintenance treatment of patients with COPD (including chronic bronchitis and emphysema), maintenance treatment of associated dyspnoea and for prevention of exacerbations.